GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

How Are Clinical Trials Regulated in Japan?

Japan regulates clinical trials through legal requirements for ethics review, informed consent, safety monitoring, and regulatory oversight. Trials intended to support product approval (chiken) follow the Pharmaceuticals and Medical Devices Act (PMD Act) 335AC0000000145 and Good Clinical Practice (GCP) 000152996.pdf. Other qualifying studies follow the Clinical Trials Act 429AC0000000016; regenerative-medicine research outside the PMD Act trial framework may instead fall under the Act on the Safety of Regenerative Medicine (ASRM) 425AC0000000085.

The Ministry of Health, Labour and Welfare (MHLW) administers these frameworks and grants marketing approvals; the Pharmaceuticals and Medical Devices Agency (PMDA) conducts scientific reviews and compliance assessments 0001. The Japan Registry of Clinical Trials (jRCT) provides public study information En top. Ethics review, a trial notification, and registry entry are different steps: none alone proves that an intervention works.

How Are Clinical Trials Regulated in Japan?

Which rules apply?

The study purpose, product, funding, and intervention determine the applicable framework. The table summarizes the main pathways; it is not an exhaustive classification of all human research. An ASRM plan may cover research or treatment, so its purpose matters as much as its registration number.

Route Legal basis Review and filing Public record Legal effect
Approval trial (chiken) PMD Act, Article 80-2; GCP IRB review; CTN to the MHLW, with PMDA review jRCT Applicable first CTNs have a 30-day waiting period; marketing approval is separate.
Specified clinical research (tokutei rinshō kenkyū) Clinical Trials Act (Act No. 16 of 2017) Certified review board (CRB) review; trial plan to the MHLW jRCT CRB opinion and plan filing. Marketing approval is separate.
Other human research within the Ethical Guidelines Ethical Guidelines for Medical and Biological Research Involving Human Subjects Institutional ethics review Varies Ethics review. Product approval is separate.
Regenerative-medicine research or treatment under the ASRM ASRM (Act No. 85 of 2013) Certified committee review; plan filed under the ASRM jRCT for research; MHLW published-plan information for treatment Class I: a 90-day pre-provision period. Product approval is separate.

The Clinical Trials Act also includes non-specified clinical research, with an obligation to endeavor to meet its standards. A study does not automatically fall outside that Act simply because it is not specified clinical research 429AC0000000016.

Approval trials

The protocol and the ethics board

A trial starts with a protocol. It has to spell out the question, the design, the endpoints, who can join, the sample size, stopping rules, and the safety plan. For drug trials, the institutional review board (IRB) has at least five members, including a lay member and someone independent of the institution. It reviews the protocol and the consent documents for ethical and scientific soundness 000152996.pdf. A paid PMDA consultation is optional. It is not an approval 0002.

The 30-day wait

For trials subject to notification, the sponsor submits a clinical trial notification (CTN) to the MHLW through PMDA. Article 80-2 establishes a 30-day waiting period for a first notification concerning the drug in question, with corresponding provisions for devices and regenerative medical products. The applicable notification category matters; this is not a new 30-day wait for every site, amendment, or study of an already-notified product 335AC0000000145. Expiry of the waiting period does not replace GCP requirements or resolve an outstanding regulatory concern.

GCP while the trial runs

Once the trial is running, GCP sets the rules. Japan has separate ordinances for drugs, devices, and regenerative products. For drug trials, duties are shared among the sponsor, institution, and investigators. They include IRB oversight, written informed consent, arrangements for trial-related injury compensation, monitoring, audits, safety reporting, and records. Investigators must follow the protocol 000152996.pdf. A foreign sponsor needs an in-country representative, and marketing applications are in Japanese 000152996.pdf 0004. The PMDA also runs GCP inspections and data-integrity checks 0001.

Marketing approval comes later

Trial data can support a marketing application. Marketing approval is a separate decision. The PMDA reviews quality, efficacy, and safety. The MHLW can approve or refuse the application, and the review may require more data 335AC0000000145 0001 0001. Approval is tied to a product and an indication. It does not approve a clinic 0001.

Specified clinical research

The Clinical Trials Act took effect on April 1, 2018. Within its scope, specified clinical research includes studies of unapproved products or off-label uses outside the statutory low-risk exclusion. It also includes research funded by a product’s manufacturer/marketing authorization holder or a legally defined related party when the study uses a product that company markets or intends to market. Not every industry grant triggers this category 429AC0000000016 0000163417.

A certified review board (CRB) reviews the study’s ethical and scientific acceptability. The responsible research organization must obtain the required opinion and submit an implementation plan to the MHLW before starting specified research. The framework requires arrangements for injury compensation and conflicts of interest 429AC0000000016. MHLW’s current conflict-of-interest notice took effect on April 20, 2026 0000163417.

Specified studies are registered in jRCT En top. Researchers must obtain informed consent, protect personal data, maintain records, and submit periodic reports. Safety reporting duties depend on the event and applicable criteria: reporting to the CRB and reporting to the Minister are not identical requirements for every adverse event 429AC0000000016.

MHLW can require corrective measures and, where statutory conditions are met, suspend or stop specified research. The Act also provides penalties for particular violations 429AC0000000016.

Other studies may fall under the Ethical Guidelines, but classification requires checking the Clinical Trials Act and any other applicable law first. Under the Guidelines, interventional research generally requires prospective registration; registration of other research is encouraged rather than universally mandatory. A limited non-disclosure exception also exists 001457376.pdf.

What changed in 2025

Act No. 51 of 2024 was promulgated on June 14, 2024, and took effect on May 31, 2025. It narrowed the off-label category where uses meet prescribed criteria for risk no greater than approved use; this is not an exemption researchers can assume for themselves, and the relevant manufacturer-funding criterion remains separate. It also extended ASRM coverage to qualifying in vivo gene therapy and clarified that added, substantially burdensome research tests can bring a study of routine-care products within the Clinical Trials Act 001506521.pdf.

The amended framework also introduced an overall study manager responsible for coordinating the research. Existing studies have transitional arrangements; do not assume that a study automatically changed category on the effective date 001506521.pdf.

Regenerative medicine

Regenerative medicine has its own route. The ASRM covers treatment or research outside a PMD Act trial, including qualifying processed-cell and nucleic-acid technologies, subject to statutory exclusions 425AC0000000085 001527354.pdf. It uses three risk classes. Classes I and II require a specially certified committee; Class III uses a certified committee. Class I cannot start until the 90-day post-filing period passes, unless the MHLW extends or shortens it 425AC0000000085 001527354.pdf.

An ASRM provision plan can cover clinical research or treatment; it is not a PMD Act trial notification or a product approval. The MHLW publishes the provider, treatment and risk class, reviewing committee, consent documents, and orders 0000186471. To match a plan to its provider, committee, and consent documents, use the registration and compliance checklist. An approved regenerative product is a separate category 0000186471 0001 0003.

What you can check

The consent form should tell you what the study is, why it is being done, and how it is designed. It should cover the possible benefits and harms, alternatives, how long you will be involved, your right to withdraw, confidentiality, access to your records, injury care and compensation, costs, and who reviewed the study. It cannot ask you to waive your legal rights 000152996.pdf. Specified research has its own consent, compensation, and personal-data rules 429AC0000000016.

The consent form

Before you sign, you should be able to answer four questions:

  • Which legal framework applies, and what is the registry or provision-plan number?
  • Who reviewed the protocol, and what did they require?
  • What is covered if something goes wrong, and who pays?
  • Can I withdraw, and what happens to my data and care?

Ask for the compensation section in writing. If the team will not provide it, that is a reason to pause.

What a review does not prove

  • A CTN is not an approval. It is a notification with a review window 335AC0000000145.
  • A CRB opinion is not proof that a treatment works. It is an ethics and science review 429AC0000000016.
  • An ASRM plan is not product approval. It may cover research or treatment 0000186471.
  • Registration is not proof of efficacy. A jRCT record can include results or result links, but the existence of a record is not a positive finding En top 001457376.pdf.
  • PubMed indexing is not a quality grade. It does not make a study well designed or a good fit for you.

Animal or laboratory results do not prove benefit in people. Human evidence has to match the disease, the stage, the cell type, the dose, the route, and the endpoint.

Check a trial claim

A jRCT entry, a CTN filing, and an ASRM plan are three different records 335AC0000000145 429AC0000000016 0000186471.

Claim What to check Why it matters
“This clinic runs a clinical trial” Ask for the registry name and number. In jRCT, check the sponsor, status, sites, and contact En top. Use it to find the trial office, not to judge benefit.
“The study is MHLW-registered” Ask which record: CTN, Clinical Trials Act plan, or ASRM plan 335AC0000000145 429AC0000000016 0000186471. The review body and legal effect differ.
“The trial is approved” Ask whether “approved” means ethics review, completion of a CTN review, or product marketing approval 335AC0000000145 0001. Those are different legal steps.
“The trial is free” Ask what is covered and how trial-related injury is handled 000152996.pdf 429AC0000000016. “Free” may mean the product only.
“The trial proves it works” Check the disease and population, cell/product type, dose and route, phase, sample size, comparator, endpoints, follow-up, and adverse events. Review and registration are not efficacy.

Finding a study is separate from checking a claim. The practical steps for finding and applying for stem cell clinical trials in Japan start with the registry record and the trial office, not a quote.

A practical registry check

On jRCT’s English search page, the available filters include target disease, recruitment status, and the medical institution’s prefecture. Its notice directs readers to the JPRN search portal to search other Japanese registry information, including UMIN-CTR. These are public tools you can use without relying on a clinic’s description En top.

For example, if an offer says “a recruiting stem-cell trial in Tokyo,” search the supplied study identifier and compare the disease, intervention, institution, recruitment status, and listed contact with the offer. If the entry says recruitment has ended, ask the listed trial office whether the record is outdated or the offer concerns a different study. If only an ASRM treatment-plan number is supplied, ask for the research record before treating the offer as a trial. This is a hypothetical checking scenario, not a report of a patient or clinic investigation.

Keep the record link and date you checked it. Ask the study office to explain discrepancies before arranging travel or paying fees. A missing search result needs clarification; it does not, by itself, prove that a study is unlawful.

Common questions

Is trial participation the same as routine treatment?

No. A trial may provide a treatment intervention, but its purpose is to answer a research question. The consent discussion must explain the experimental aspects, foreseeable risks, possible benefits, and alternatives; individual benefit is uncertain 000152996.pdf.

Are all trials in jRCT?

No. jRCT includes PMD Act trials, specified clinical research, and ASRM research, but it is not the only Japanese registry. Its own search notice points to the JPRN portal for cross-searching UMIN-CTR. Ask the study office which registry and legal framework apply En top.

Can foreign patients join?

Maybe. The protocol and the institution decide who can join, what language support exists, and what travel and follow-up are possible. Ask the trial office 0004.

Cost and time

There is no universal free trial and no fixed total. The product may be supplied, but tests, travel, and follow-up may not be, and approval does not mean reimbursement. The 30-day figure covers only the first CTN review. Site setup and enrollment are separate 335AC0000000145 000152996.pdf 0001 0004.

The main point

Before considering a study, identify its legal framework, reviewing board, public record, and responsible institution. Then read the consent information and ask about costs, injury arrangements, and withdrawal. Regulatory oversight provides safeguards for research; it cannot promise benefit to an individual participant.

Questions before you decide

For questions about this clinic’s services or language support, contact its international patient team. For trial eligibility or confirmation of a study’s status, use the investigator or trial office listed in the official registry.

Contact the patient support team

Scope and limits

This overview concerns Japan and was checked against the official sources below on October 24, 2026. English translations may predate amendments; the current Japanese legislation controls. It is not individual legal or medical advice. This website belongs to a private clinic and has a commercial interest in patient enquiries; its services are not regulatory oversight or independent trial review.

Sources

Official Japanese sources consulted on October 24, 2026. The drug GCP translation is a reference translation; current laws and implementation guidance determine the requirements for a particular study.

  1. Pharmaceuticals and Medical Devices Act (Act No. 145 of 1960), e-Gov. Accessed October 24, 2026. https://laws.e-gov.go.jp/law/335AC0000000145
  2. Ministerial Ordinance on Good Clinical Practice for Drugs (MHLW Ordinance No. 28 of 1997, as amended), PMDA provisional English translation, January 2023. Accessed October 24, 2026. https://www.pmda.go.jp/files/000152996.pdf
  3. Clinical Trials Act (Act No. 16 of 2017), current Japanese text, e-Gov. Accessed October 24, 2026. https://laws.e-gov.go.jp/law/429AC0000000016
  4. Act on the Safety of Regenerative Medicine (Act No. 85 of 2013), e-Gov. Accessed October 24, 2026. https://laws.e-gov.go.jp/law/425AC0000000085
  5. PMDA, Outline of Reviews and Related Services. Accessed October 24, 2026. https://www.pmda.go.jp/english/review-services/outline/0001.html
  6. Japan Registry of Clinical Trials (jRCT), English top page. Accessed October 24, 2026. https://jrct.mhlw.go.jp/en-top
  7. PMDA, Consultations. Accessed October 24, 2026. https://www.pmda.go.jp/english/review-services/consultations/0002.html
  8. PMDA, Frequently Asked Questions (FAQ). Accessed October 24, 2026. https://www.pmda.go.jp/english/about-pmda/0004.html
  9. PMDA, GLP/GCP/GPSP Compliance Assessments. Accessed October 24, 2026. https://www.pmda.go.jp/english/review-services/glp-gcp-gpsp/0001.html
  10. PMDA, Information for Approved Products. Accessed October 24, 2026. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0001.html
  11. MHLW, Clinical Trials Act, including enforcement date and 2026 conflict-of-interest update. Accessed October 24, 2026. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000163417.html
  12. Ethical Guidelines for Medical and Biological Research Involving Human Subjects (2021, partially amended 2023), MHLW. Accessed October 24, 2026. https://www.mhlw.go.jp/content/001457376.pdf
  13. MHLW, Explanation of the Clinical Trials Act Amendments, including the May 31, 2025 changes, transitional arrangements, and overall study manager. Accessed October 24, 2026. https://www.mhlw.go.jp/content/10800000/001506521.pdf
  14. MHLW, Overview of the Act on the Safety of Regenerative Medicine, including enactment and effective dates, risk classes, and committee routes. Accessed October 24, 2026. https://www.mhlw.go.jp/content/10800000/001527354.pdf
  15. MHLW, Information on Regenerative Medicine Providers, including published plan information and consent documents. Accessed October 24, 2026. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000186471.html
  16. PMDA, Regenerative Medical Products, including the approved-product list and review reports. Accessed October 24, 2026. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0003.html